DUBLIN, Nov. 9, 2023 /PRNewswire/ — The “Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets” report has been added to ResearchAndMarkets.com’s offering.
The global Biologics Contract Development and Manufacturing Organization (CDMO) market witnessed remarkable growth, reaching a value of nearly $13.4 billion in 2022. A new report reveals that this market is set to skyrocket with a projected Compound Annual Growth Rate (CAGR) of 12.3%, ultimately reaching an impressive $27 billion by the close of 2028.
Several factors are propelling this exponential growth, including increased Research and Development (R&D) activities, a rising prevalence of chronic diseases, surging demand for biologics, an aging population, continuous investments in healthcare infrastructure, and a steady influx of innovative products.
In particular, the North American Biologics CDMO market is poised for a substantial boost, with projections indicating a growth from $6.6 billion in 2023 to $12.4 billion by the end of 2028, driven by a robust CAGR of 13.2% during the forecast period.
Similarly, the Asia-Pacific Biologics CDMO market is anticipated to surge from $3.1 billion in 2023 to $5.9 billion by 2028, displaying an impressive CAGR of 13.7% during the same forecast period.
This comprehensive report, titled “Global Biologics CDMO Market Report 2020-2028,” provides insights into the market’s dynamics, offering a detailed segmentation based on product type, cell line type, and geographic region. Key product categories encompass biologics and biosimilars.
Notably, Biologics CDMO companies are collaborating closely with pharmaceutical and biotechnology firms to facilitate drug development. An example includes ChimeronBio’s manufacturing agreement with FujiFilm Diosynth Biotechnologies (FDB) to expand its oncology portfolio.
The report further categorizes the global market for Biologics CDMO by cell line type, including mammalian, microbial, and other modalities. The mammalian segment is projected to grow from $8.7 billion in 2022 to $18.2 billion by 2028, boasting a CAGR of 12.9% over this period.
Companies Mentioned
Abbvie Pharmaceutical Contract Manufacturing
Agc Biologics
Boehringer Ingelheim Bioxcellence
Binex Co. Ltd.
Biovian Oy
Bora Pharmaceutical Cdmo
Catalent Inc.
Cytovance Biologics
Emergent Bioservices
Fujifilm Diosynth Biotechnologies
Icon PLC
Jrs Pharma GmbH & Co. KG
Kemwell
Lonza Group
Lotte Biologics
Parexel International Corp.
Rentschler Biopharma SE
Samsung Biologics
Sandoz International GmbH
Thermo Fisher Scientific Inc.
Toyobo Co. Ltd.
Wuxi Xdc
Key highlights of the report include:
An in-depth overview and industry analysis of the global Biologics CDMO market
Analysis of global market trends, historical market revenue data for 2022, estimates for 2023, forecasts for 2024, and projections of CAGRs through 2028
Market size estimations and revenue forecasts for the Biologics CDMO market in USD million values, with corresponding market share analysis based on product type, cell line type, and geographic region
Comprehensive insights into market growth drivers, opportunities, challenges, prospects, technologies, regulatory scenarios, and macroeconomic variables’ impact on the Biologics CDMO market
Discussion of Environmental, Social, and Governance (ESG) developments in the global CDMO services market, highlighting ESG importance, consumer attitudes, risks and opportunities, and ESG practices
Identification of pharmaceutical companies recognized as industry leaders, along with their technological strategies for market dominance
Market outlook and opportunity assessment of industry structure for Biologics CDMO services, evaluation of ongoing clinical trials, and R&D activities estimating current and future market demand
Insights into growth development strategies of key market players, competitive landscape, and company share analysis
Company profiles of major industry players, including Lonza Group, WuXi Biologics, Samsung Biologics, Boehringer Ingelheim, and Catalent Inc.
Key Attributes:
|
Report Attribute |
Details |
|
No. of Pages |
131 |
|
Forecast Period |
2023 – 2028 |
|
Estimated Market Value (USD) in 2023 |
$15.1 Billion |
|
Forecasted Market Value (USD) by 2028 |
$27 Billion |
|
Compound Annual Growth Rate |
12.3 % |
|
Regions Covered |
Global |
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Introduction
Benefits of Biologics CDMOs
Expertise
Equipment and Manufacturing Facilities
Scalability
Benefits of Outsourcing
Drawbacks to Outsourcing
Contract Manufacturing
Types of Contract Manufacturers
Evolution of Contract Manufacturing Organizations
Outsourcing
Criteria for Evaluating a Contract Manufacturer
Core Capabilities of CMOs
Core Functional Areas Requiring Constant Attention
Criteria for Selecting an Outsourcing Partner
Top Sources of Dissatisfaction
Challenges in Contract Manufacturing
Services Offered by CMOs
Contract Research
Selecting a CRO
Services Offered by CROs
Checklist for Selecting a CRO
Benefits of Using a CRO
Client/CRO Relationship
Chapter 4 Market Dynamics
Market Drivers
Rising Prevalence of Cancer
Increasing Demand for Biologics
Rising Use of CDMOs
Increasing Elderly Population
Market Restraints
Biologic Product Costs and Price Controls
Capacity Constraints
Manufacturing Costs
Market Opportunities
Co-development of Biosimilars
Chapter 5 Global Market for Biologics CDMOs by Product Type
Introduction
Biologics
Biosimilars
Biologics
Biosimilars
Chapter 6 Global Market for Biologics CDMOs by Cell-Line Type
Mammalian
Microbial (Non-mammalian)
Other Modalities
Chapter 7 Global Market for Biologics CDMOs by Region
Market Overview and Discussion
North America
Europe
Asia-Pacific
RoW
Chapter 8 Sustainability in Biologics CDMOs: An ESG Perspective
Introduction to ESG
Sustainability in Biologics CDMO Industry: An ESG Perspective
Key ESG Issues
Attitudes toward ESG
Industry ESG Performance Analysis
Toyobo and ESG
Concluding Remarks
Chapter 9 Emerging Technologies and Developments
Overview
Big Data, AI and ML
Single-use Technology
Process Analytical Technology (PAT)
Chapter 10 Regulatory Landscape
Regulation of Biologics Services
FDA Regulations
European Regulations
Impact of FDA Regulations
The Declaration of Helsinki
CDISC Standards
Chapter 11 M&A and Venture Funding Outlook
M&A Analysis
Recent News
Chapter 12 Competitive Intelligence
Chapter 13 Company Profiles
Chapter 14 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/arqcd6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
